New Alzheimer's clinical trials to be undertaken by NIA nationwide consortium.
D000368:Aged; D000375:Aging / Q000502:physiology; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018450:Disease Progression; D004281:Docosahexaenoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D016651:Lithium Carbonate / Q000627:therapeutic use; D009316:National Institutes of Health (U.S.); D014481:United States; D014635:Valproic Acid / Q000627:therapeutic use
D014150:Antipsychotic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D016756:Immunoglobulins, Intravenous; D004281:Docosahexaenoic Acids; D016651:Lithium Carbonate; D014635:Valproic Acid